N ebivolol (NEB) is a third-generation highly selective β 1-adrenergic receptor blocker with vasodilating characteristics.
to (1) LS+vehicle, (2) HS+vehicle, (3) HS+mitramycin (Sp1 inhibitor; 0.25 mg/kg per day), and (4) HS+ML-141 (ML, Cdc42 inhibitor; 0.5 mg/kg per day).
Echocardiography
Trans-thoracic echocardiography was performed under anesthesia (online-only Data Supplement). 5 
miRNA Microarray
After 2 months of treatment, rats were euthanized; total RNA samples from the myocardium were extracted by Trizol reagent and 10 µ g of RNA samples sent to L.C. Sciences for miRNA microarray (see online-only Data Supplement).
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction
We used a different set of animals, treated as above, to confi rm the results of the miRNA arrays by quantitative reverse transcription polymerase chain reaction (see online-only Data Supplement).
Luciferase Assay
Luciferase assay was performed to determine the effects of miRNAs on reporter genes (see online-only Data Supplement).
In Vitro Studies
The effects of overexpression of miR-27a, -29a, and -133a on Cdc42 and Sp1 and cell surface area in cardiomyocytes, and the expression of collagen in cardiac myofi broblasts were determined (see onlineonly Data Supplement). The effects of pharmacological inhibition of Sp1 and Cdc42 on angiotensin (ANG)-2 -induced hypertrophy in cardiomyocytes were also examined (see online-only Data Supplement).
Statistical Analysis
See online-only Data Supplement.
Results

Blood Pressure, HR, Hypertrophy, and Fibrosis
Eight animals were included in each group. Three animals in the HS and 1 in the ATN group died before completing the protocol. HS increased SBP, starting at week 8 (2 weeks after starting HS; Figure S1A in the online-only Data Supplement). NEB and ATN reduced SBP to a similar extent. HR was not affected by HS. Both NEB and ATN similarly decreased HR ( Figure S1B ). HS increased heart/body weight ratio. NEB completely, and ATN partially, reversed the effect ( Figure  S1C ). HS increased cardiomyocyte size ( Figure S2 ). Both NEB and ATN prevented the increase in cardiomyocyte size. HS induced cardiac fi brosis ( Figures S1D and S3 ). NEB attenuated fi brosis more than ATN.
Echocardiography
Two animals in the HS group died before completion of the protocol. HS caused LV dilatation, an increase in posterior wall thickness and a signifi cant decrease in LV systolic function (Table S1 ). Both NEB and ATN attenuated LV remodeling. The benefi cial effect of NEB on LV internal dimension in diastole, LV internal dimension in systole, fractional shortening, and LV ejection fraction was signifi cantly greater than that of ATN.
Alterations of Expression of miRNAs Induced by HS Are Reversed by NEB and ATN
miRNA microarray showed signifi cant changes ( P < 0.01) in the expression of 18 miRNAs in the HS compared with the LS group. NEB attenuated these changes in 6 and ATN in 4 of these miRNAs. On the basis of their expression levels and the magnitude of alterations by HS with and without NEB or ATN, we decided to focus on 3 miRNAs that were downregulated by HS compared with the LS group ( Figure S4 ).
To confi rm the microarray results, the expression of the 3 selected miRNAs was measured by quantitative reverse transcription polymerase chain reaction ( Figure 1 ). Levels of miR-27a, -29a, and -133a were decreased in the HS group. NEB, but not ATN, prevented the HS-induced decrease in miR-27a. ATN only partially, whereas NEB completely reversed the HS-induced decreased in miR-29a. Both NEB and ATN prevented the decrease in miR-133a without a signifi cant difference between NEB and ATN.
Identify the Targets for Dysregulated miRNAs
According to TargertScanHuman ( http://www.targetscan. org/ ), in the rat ( Rattus norvegicus ), MiR-27a has 1808 targets, miR-29a 1080 targets, and mir-133a has 834 potential targets. We identifi ed Sp1 (targeted by miR-29a and -27a) and Cdc42 (targeted by miR-133a) as candidate targets. MiR-29a and -27a signifi cantly repressed luciferase activity when cotransfected with 3 ′ -untranslated regions of Sp1 ( Figure 2A and 2B ) . MiR-133a repressed luciferase activity of Cdc42 ( Figure 2C ). Sp1 and Cdc42 protein levels were signifi cantly increased by HS ( Figure 3A and 3C ). The increase was reversed by NEB Figure 1 . A , MicroRNAs (miRNA) array (n=3 in each group). B , Quantitative reverse transcription polymerase chain reaction (qRT-PCR; n=4 in each group). Overall, there were signifi cant differences among the treatment groups for each of the 3 miRNA tests ( P < 0.002). * P < 0.05 vs control; † P < 0.05 vs high-salt (HS); and ‡ P < 0.05 vs nebivolol (NEB). ATN indicates atenolol.
and Sp1 and cell surface area in cardiomyocytes, and the expression of collagen in cardiac myofi broblasts were determined (see onlineonly Data Supplement). The effects of pharmacological inhibition of Sp1 and Cdc42 on angiotensin (ANG)-2 -induced hypertrophy in cardiomyocytes were also examined (see online-only Data Supplement).
Statistical Analysis
Results
Blood Pressure, HR, Hypertrophy, and Fibrosis
Eight animals were included in each group. Three animals in the HS and 1 in the ATN group died before completing the 3 selected miRNAs was measured by quantitative reverse transcription polymerase chain reaction ( Figure 1 ). Levels of miR-27a, -29a, and -133a were decreased in the HS group. NEB, but not ATN, prevented the HS-induced decrease in miR-27a. ATN only partially, whereas NEB completely reversed the HS-induced decreased in miR-29a. Both NEB and ATN prevented the decrease in miR-133a without a signifi cant difference between NEB and ATN. more than by ATN. In parallel, NEB more than ATN inhibited HS-induced increase in collagen-I expression.
Overexpression of miR-27a, -29a, and -133a Reduces the Expression of Collagen and Prevents Hypertrophy of Cardiomyocytes in an In Vitro Model
We used an in vitro model to assess the effects of miR-27a, -29a, and -133a on ANG-induced hypertrophy. Transfection of cells with Lent-27a, Lent-29a, and Lent-133a attenuated the ANGinduced upregulation of collagen-I and -III mRNA in cardiac fi broblast ( Figure S5D and S5E) . ANG induced upregulation of Cdc42 and Sp1 protein levels ( Figure S5F and S5F). Lent133a attenuated the increase in Cdc42, and both Lent-27a and Lent-29a suppressed the increase in Sp1. ANG induced cardiomyocyte hypertrophy. Lent-27a, Lent-29a, and Lent133a attenuated hypertrophy, whereas Lent-mock had no effect ( Figure S6H and S6I).
HS-Induced Fibrosis and Hypertrophy Are Mediated by Sp1 and Cdc42
Inhibition of Sp1 by mitramycin and Cdc42 by ML reduced HS-induced fi brosis and hypertrophy ( Figure 3E and 3F) . To confi rm the results of the in vivo study and to control for potential confounders, we used an in vitro model of ANGinduced hypertrophy in cardiomyocytes ( Figure S6 ). ANG induced cell hypertrophy. Both mitramycin and ML attenuated the ANG effect.
Discussion
Despite having similar effects on SBP and HR, NEB completely, and ATN only partially, prevented HS-induced LV hypertrophy, fi brosis, and remodeling. HS decreased the expression of miR-27a, -29a, and -133a. NEB, but not ATN, prevented the HS-induced decrease in miR-27a. NEB completely, whereas ATN only partially attenuated the HS-induced decrease in miR-29a. Both NEB and ATN attenuated the HS-induced decrease in myocardial miR-133a levels.
MiRNA alterations are part of a complex network response intended to regulate multiple gene expression. As simultaneous changes in several miRNAs are observed in response to various stimuli and each miRNA may target several mRNAs, fi nal outcomes are complex. 6 Furthermore, although some of the observed increases and decreases may play a role in the pathophysiology of the disease, they could also play important roles as part of defense mechanisms against injury. Overexpression of the β 1-adrenergic receptors has been shown to alter miRNA expression that may affect the development of cardiomyopathy. In particular, overexpression of the β 1-adrenergic receptors lead to downregulation of miR-133 expression, as seen in our model. 7 Previous studies have shown that propranolol, a nonselective β -blocker, normalized the expression of various dysregulated miRNAs after experimental myocardial infarction, including miR-1, -29b, and -98. 8 , 9 However, the effects of β -blockers on miRNA expression in a model of hypertension have not been described.
MiR-27a
Twelve weeks after starting the HS diet, miR-27a levels were lower in the HS group. NEB, but not ATN, restored miR-27a to basal levels. Previous studies suggested that 7, 14, and 21 days after aortic banding in the mouse miR-27a levels were increased. 10 , 11 Thus, there might be differences between species or hypertension experimental models. Alternatively, different changes may have been detected at different time points after induction of hypertension.
MiR-29a
MiR-29s targets at least 16 extracellular matrix genes and have been reported to possess strong antifi brotic effects in various tissues. 12 Twelve weeks after starting HS diet, miR-29a pletely, whereas ATN only partially attenuated the HS-induced decrease in miR-29a. Both NEB and ATN attenuated the HS-induced decrease in myocardial miR-133a levels.
MiRNA alterations are part of a complex network response intended to regulate multiple gene expression. As simultaneous changes in several miRNAs are observed in response to various stimuli and each miRNA may target several mRNAs, fi nal outcomes are complex.levels were lower in the HS group than in the control group. NEB completely and ATN partially restored miR-29a levels. Our results confi rm results of Cheng et al 10 in mice with transaortic banding; however, using a similar model, Tatsuguchi et al 13 reported an increase in miR-29a 2 and 4 weeks after transaortic banding; the discrepancy could point to a biphasic response to induction of hypertension, a common feature of stress -response mechanisms.
MiR-133a
MiR-133a levels were lower in the HS group than in the control group. Both NEB and ATN restored myocardial miR-133a levels. Our results confi rm the results obtained in several different models of hypertension in mice and rats. 10 , 11 , 14 , 15 Our luciferase assay confi rmed the results of a previous study that miR-133a regulates Cdc42 expression. 15 MiR-133a is also known to regulate CTGF, 14 RhoA, and Nelf-A/WHSC2, 15 all are implicated in cardiac hypertrophy. Transgenic expression of miR-133a attenuates transverse aortic constriction -induced myocardial fi brosis and apoptosis and deterioration of diastolic function.
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Sp1
Sp1 gene is targeted by both miR-29a and -27a. Sp1 is a transcriptional regulator that determines cell cycle progression and proliferation. 17 , 18 Sp1 is involved in the regulation of expression of c-fos, which interacts with the universal cell cycle gene RB (retinoblastoma gene product) to regulate mitosis. 17 , 19 ANG induces a time-dependent upregulation of Sp1 in cardiac fi broblasts. 19 Sp1 expression is increased in hypertrophied cardiac muscle of Western ewes with high cardiac output induced by aortopulmonary fi stula. Sp1 activates the cardiac troponin-T promotor. 20 Myocardial Sp1 levels are increased in rats with aortic banding and in neonatal cardiomyocytes exposed to phenylephrine. 21 Our data confi rm a previous report that HS diet increases myocardial Sp1 levels in Dahl salt-sensitive hypertensive rats. 22 However, previous studies have not demonstrated that Sp1 inhibition affects cardiac hypertrophy or fi brosis. Here, we show that mitramycin (an Sp1 inhibitor) 23 attenuated left ventricular hypertrophy and fi brosis in vivo and in vitro, suggesting a causal relation. We are also showing that in vitro overexpression of miR-27a and -29a attenuated ANGinduced upregulation of Sp1 levels and collagen in cardiac myofi broblasts. Thus, the benefi cial effect of NEB over ATN could be explained (at least in part) by upregulation of miR29a and -27a, with subsequent suppression of Sp1.
Cdc42
Here, we confi rm that Cdc42 is targeted by miR-133a. It has been shown that Cdc42 is also targeted by miR-29.
12 Cdc42 is a member of the Rho subfamily of small guanosine triphosphatase (GTPase) proteins 24 and is involved in the regulation of the actin/myosin cytoskeleton in many cell types.
25
Cdc42 is involved in collagen-1 secretion from cells. 26 Cdc42 mediates leukocyte inhibitory factor -induced and phenylephrine-induced hypertrophic response in cultured neonatal rat cardiomyocytes. 27 Cdc42 overexpression also enhances myocyte growth in culture, whereas overexpression of a dominant-negative Cdc42 mutant reduced leukocyte inhibitory factor -induced myocyte growth in rat cardiomyocytes. 27 However, Maillet et al 28 reported contrary fi ndings. They also found that Cdc42 is upregulated in the heart after pressure overload stimulus and in cultured cardiomyocytes by various agonists; however, cardiomyocyte-specifi c deletion of Cdc42 in adult mice enhanced cardiac hypertrophy and fi brosis in response to both pathological and physiological stimuli. 28 Their results suggest that Cdc42 has a protective role and upregulation of Cdc42 is secondary, not the cause for the hypertrophic stimulus. Our fi ndings are in accordance with the previous studies that HS-induced hypertension increases myocardial levels of Cdc42. Our in vitro experiment shows that overexpression of miR-133a attenuated ANG-induced overexpression of Cdc42. We found that pharmacological inhibition of Cdc42 with . There were 4 animals in each group. * P < 0.05 vs control; † P < 0.05 vs high-salt (HS); and ‡ P < 0.05 vs nebivolol (NEB). E , Densitometric analysis of the extent of fi brosis (n=6 in each group). Overall, there were signifi cant differences among the groups ( P < 0.001). F , Heart weight (HW)/ body weight (BW) ratio. Overall, there were signifi cant differences among the groups ( P < 0.001). * P < 0.05 vs control and † P < 0.01 vs HS. ATN indicates atenolol; and MIT, mitramycin.
NEB completely and ATN partially restored miR-29a levels. Our results confi rm results of Cheng et al 10 in mice with transaortic banding; however, using a similar model, Tatsuguchi reported an increase in miR-29a 2 and 4 weeks after transaortic banding; the discrepancy could point to a biphasic response to induction of hypertension, a common feature of stress -response mechanisms.
MiR-133a levels were lower in the HS group than in the control group. Both NEB and ATN restored myocardial miR-133a levels. Our results confi rm the results obtained in several different models of hypertension in mice and rats. 10 , 11 , 14 , 15 Our Sp1 inhibition affects cardiac hypertrophy or fi brosis. Here, we show that mitramycin (an Sp1 inhibitor) ventricular hypertrophy and fi brosis in vivo and in vitro, suggesting a causal relation. We are also showing that in vitro overexpression of miR-27a and -29a attenuated ANGinduced upregulation of Sp1 levels and collagen in cardiac myofi broblasts. Thus, the benefi cial effect of NEB over ATN could be explained (at least in part) by upregulation of miR29a and -27a, with subsequent suppression of Sp1.
Cdc42
Here, we confi rm that Cdc42 is targeted by miR-133a. It has been shown that Cdc42 is also targeted by miR-29. ML-141 (a potent and selective inhibitor of Cdc42) 29 prevented cardiac hypertrophy and fi brosis in the Dahl salt-sensitive hypertensive rats and prevented hypertrophy in vitro in a model of ANG-induced hypertrophy of adult rat cardiomyocytes. Our results are in agreement with Lengfeld et al 26 who showed that Cdc42 is essential for collagen-1 secretion. It is possible that Cdc42 has different roles in different animal species or models; as mentioned above, it was previously reported that Cdc42 induces hypertrophy in the rat, 27 whereas it attenuated hypertrophy in the mouse. 28 Alternatively, we cannot exclude that ML-141 could affect other mediator(s) involved in fi brosis and hypertrophy. Interestingly, NEB had a greater effect on Cdc42 levels than ATN, despite the fact that the effects of NEB and ATN on miR-133a levels were comparable. The greater effect of NEB on miR-29a levels may be the explanation, as miR-29 also targets Cdc42. 12 We cannot exclude that mediators other than miR-133a also affect Cdc42 levels.
The fact that, despite similar effects on blood pressure and HR, the alterations in miR-27a and -29a expression were different between NEB and ATN suggests that those changes are not merely secondary to the decrease in SBP and antagonism of the β 1-receptors. The differences in effi cacy, favoring NEB over ATN, might be (partially) explained by the unique effect of NEB on miR-27a and its greater effect on miR-29a levels. It is yet to be determined whether the benefi cial effects of NEB on miR-27a and miR-29a expression and subsequently, LV hypertrophy, fi brosis, and function are owing to the unique β 3-receptor activation or secondary to the nitric oxide -enhancing effects of NEB.
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Limitations
We used an in vitro model of simulated hypertension (incubation of cells with ANG) to assess the effects of miR-27a, -29a, and -133a on upregulation of collagen, Cdc42, and Sp1 protein levels and cell hypertrophy. Although this model has been extensively used before, the results should be interpreted cautiously because in vitro models never duplicate the complexity of the in vivo models.
Perspectives
NEB has distinct effects on profi brosis miRNA expression, as compared with fi rst generation β 1-selective ATN. In our model, NEB prevented remodeling, fi brosis, and deterioration of function more than ATN, despite similar effects on SBP and HR. Further studies are needed to show whether similar distinct effects are seen in other animal models of hypertension and in hypertensive patients, and whether these alterations in miRNA expression are translated to improved clinical outcomes in the clinical setting. What Is New?
Sources of Funding
• We are showing that despite identical effects on heart rate and blood pressure, nebivolol (NEB) had distinct favorable effects on profi brosis microRNA expression that translate to better attenuation of adverse remodeling and fi brosis as compared with a fi rst generation β 1-receptor antagonist atenolol (ATN).
What Is Relevant?
• Several small studies have suggested that NEB may have better effects on remodeling and vascular reactivity than other β blockers. The distinct effects on the expression of profi brosis microRNA may be an explanation, as microRNAs control diverse aspects of cell survival and differentiation.
Summary
Hypertension, induced by high-salt diet, decreased the myocardial expression of miR-27a, -29a, and -133a. NEB, but not ATN, prevented the high-salt -induced decrease in miR-27a and -29a. Both NEB and ATN attenuated the high-salt -induced decrease in myocardial miR-133a levels. NEB attenuated cardiac fi brosis, hypertrophy, and remodeling more than ATN, despite similar effects on systolic blood pressure and heart rate. The beneficial effect of NEB over ATN can be explained by upregulation of miR-29a and -27a, leading to suppression of Sp1 and upregulation of miR-133a, leading to suppression of Cdc42.
Novelty and Signifi cance
microRNA expression that translate to better attenuation of adverse remodeling and fi brosis as compared with a fi rst generation β 1-receptor antagonist atenolol (ATN).
What Is Relevant?
Several small studies have suggested that NEB may have better effects on remodeling and vascular reactivity than other β blockers. The distinct effects on the expression of profi brosis microRNA may be an explanation, as microRNAs control diverse aspects of cell survival and differentiation.
prevented the high-salt -induced decrease in miR-27a and -29a. Both NEB and ATN attenuated the high-salt -induced decrease in myocardial miR-133a levels. NEB attenuated cardiac fi brosis, hypertrophy, and remodeling more than ATN, despite similar effects on systolic blood pressure and heart rate. The beneficial effect of NEB over ATN can be explained by upregulation of miR-29a and -27a, leading to suppression of Sp1 and upregulation of miR-133a, leading to suppression of Cdc42. 
NEBIVOLOL INDUCES DISTINCT CHANGES IN PRO-FIBROSIS MICRORNA EXPRESSION COMPARED TO ATENOLOL, IN SALT-SENSITIVE HYPERTENSIVE
RATS
Echocardiography
We used an HP Sonos 5500 echocardiograph. Two-dimensional and M-mode images in the parasternal short axis view at the mid-papillary level were obtained using a 15 MHz linear transducer. Key cardiac parameters, such as left ventricle (LV) internal diameters at end diastole (LVIDd) and systole (LVIDs), interventricular and posterior wall thickness, left ventricular fractional shortening (FS) and calculated ejection fraction (LVEF) by Teich method 3 were measured. MiRNA microarray: After 2 months of treatment, rats were euthanized; total RNA samples from the myocardium were extracted by Trizol Reagent. Ten µg of RNA samples were sent to L.C. Sciences for miRNA-microarray µParaflo® Microfluidic Biochip Technology 4 Samples were enriched for small RNA. Each sample was labeled with fluorescent dyes and hybridized to a single Atactic µParaFlo microfluidics chip that held 334 mature rodent miRNA probes. Perfectly matched and mismatched probes were used for quality control. The raw data represented the average of 5 signal values for each miRNA on the array. Three independent experiments were performed. The background was subtracted and normalized using LOWESS (locally weighted regression) method. ANOVA was used to test the significance of differences among groups and t-test was used to compare between individual treatments groups (no correction for multiple comparisons). Data was analyzed and miRNAs with significant expression and significant alteration by either drug were selected for further studies.
Luciferase assay
Luciferase assays were performed to determine the effects of miRNAs on reporter genes. The 3'-UTRs of target genes predicted to interact specifically with miRNAs were obtained by RT-PCR amplification. The resulting fragments were inserted into the multiple cloning sites downstream of the luciferase gene in the pMIR-REPORT TM luciferase miRNA expression reporter vector (OriGene Technologies, Inc). Luciferase assay was performed using the Luc-Pair™ miR Luciferase Assay Kit (GeneCopoeia). After 24h starvation, cells (1x10 4 /well) were transfected with: 1) 0.8 µg of target gene 3'UTR, 2) target gene 3'UTR+10nM scramble-miRNA (non-target control), 3) 3'UTR of target gene+10nM miRNA, 4) mutant target gene 3'UTR+10nM miRNA, 5) mutant target gene 3'UTR+ 10nM scramble-miRNA, 5) 3'UTR of target gene +10nM miRNA +10nM inh-miR (oligonucleotide that inhibits the specific miRNA). Cells were transferred to a 96-well plate 18h after transfection and cultured for another 24h. Both firefly luciferase and Renilla luciferase activities were determined in the HEK293 cell line. Firefly luciferase activity was then normalized to Renilla luciferase activities (normalizing control) per well. The UTR constructs used and the nucleotides that were changed for the mutant construct are depicted in the table below:
Quantitative real-time RT-PCR: Total RNA enriched with small RNAs was isolated using mirVana miRNA Isolation Kit (Ambion Austin, TX). Small RNA expression was quantified by using the mirVana™ qRT-PCR miRNA Detection Kit (Ambion Austin, TX) as described previously 5 . For real-time PCR, SYBR Green I was used for quantification of miRNA transcripts following the manufacturer's instructions. Reactions contained mirVana qRT-PCR Primer Sets were specific for miRNAs interested. QRT-PCR was performed on a GeneAmp 2400 thermocycler for 40 cycles. The appropriate cycle threshold (Ct) was determined using the automatic baseline determination feature. The successful PCR amplification of miRNA should exhibit a single prominent peak that is different from primer-dimers observed in the control reaction. The expression of individual miRNA between RNA samples was calculated. Data were normalized by evaluating U6 expression. Western blot analysis Samples were homogenized in lysis buffer (in mM): 25 Tris·HCl (pH 7.4), 0.5 EDTA, 0.5EGTA, 1 phenylmethylsulfonyl fluoride, 1 dithiothreitol, 25 NaF, 1 Na 3 VO 4 , 1% Triton X-100, 2% SDS and 1% protease inhibitor cocktail. Protein (70µg) was fractionated by SDS-PAGE (4%-20% polyacrylamide gels) and transferred to PVDF membranes (Millipore, Bedford, MA). Samples were incubated with Anti-Fas antibodies. Bound antibodies were detected using the chemiluminescent substrate (NEN Life Science Products, Boston, MA). Protein signals were quantified with an image-scanning densitometer, and normalized to the corresponding β-actin signal. Hearts were fixed with 4% paraformaldehyde overnight, and embedded in paraffin. Paraffin sections (4µm) were stained with Masson's trichrome. Frozen sections were used to visualize cardiomyocyte cell membranes by staining with TRITC-conjugated wheat-germ agglutinin (Sigma-Aldrich) to determine cell size.
Histological Analysis
Culturing cells and viral transduction
Ventricular primary cultures of cardiomyocytes were prepared from Sprague-Dawley male rats as previously described 6 . Briefly, myocytes were plated on laminin coated plate at a density of 2×104 cells/cm 2 in culture media and incubated at 37°C in 7.5% CO2 for 12h before experiments. Primary cultures for cardiac fibroblasts were setup using a modified procedure previously reported 7 . Briefly, samples from the left ventricle of adult rat hearts were finely minced and incubated in 0.1% collagenase/2%BSA in DMEM at 37 0 C for 5min, and then incubated with 0.05% collagenase/1% BSA in DMEM at 37 0 C for 35min. Cells were centrifuged at 400xg at 20 0 C for 10min. Cell pellet was triturated in DMEM containing 10% FBS and antibiotics, and then was subsequently pre-plated at 37 o C for 2h in the presence of 95% O 2 /5% CO 2 . Attached fibroblasts were allowed to grow to confluence in the culture medium. Cells from passage 4 to 7 with 70 to 80% confluence were used. We constructed lentivirus vector containing a cassette for the constitutive expression of miRNAs using a BLOCK-it Pol II miR Expression Vector Kit (invitrogen). The production of this Lentiviral system is expressing miR-27a, -29a or -133a (lent-27a, -29a or -133a) under control of the RNA Polymerase II promoter (PCMV). Lentiviral transduction procedures were performed essentially according to the manufacturer's protocol. Cardiomyocytes or cardiac fibroblasts were pretreated with lent-27a, lent-29a, lent133a or lentivirus vector (Mock) at 37°C for 24h before treatment with angiotensin-2 (ANG; 150nM)(Sigma Aldrich) for additional 24h. The titer of lentivirus was 1X10 8 IU/ml. 3µl of each lentivirus was added to 10ml medium. QRT-PCR was used to assess the success of transfection and expression of miRNAs and target genes. Immunoblotting was used to assess the expression of Sp1 and Cdc42. Cardiomyocyte cell surface area was measured to assess cellular hypertrophy. Cell images were captured at x20 magnification. Cell surface area was analyzed using Image J 1.34s (NIH) from 40 randomly selected cells. The experiments were repeated 5 times. For assessing the effects of inhibitors of Sp1 and Cdc42 on cardiomyocyte hypertrophy in vitro, ANG was added alone or together with 300nM MIT or 10µM ML. Cells were incubated for 24h, thereafter, cell surface area was evaluated as described above.
Statistical analysis:
Data from given sets were averaged and presented as means±standard error of means. Statistical significance of differences between groups was determined using either Student's t-test or analysis of variance; Analysis of variance (ANOVA) with Sidak correction for multiple comparisons was applied to compare the different groups. The differences in HR and SBP were compared using 2-way repeated measures ANOVA with Holm-Sidak multiple comparison procedures. Values of p<0.05 were considered statistically significant.
